#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Functional	_
1-2	11-23	Connectivity	_
1-3	24-26	in	_
1-4	27-35	Distinct	_
1-5	36-45	Cognitive	_
1-6	46-54	Subtypes	_
1-7	55-57	in	_
1-8	58-67	Psychosis	_
1-9	68-78	Background	_
1-10	79-80	:	_
1-11	81-90	Cognitive	_
1-12	91-102	dysfunction	_
1-13	103-105	is	_
1-14	106-112	common	_
1-15	113-115	in	_
1-16	116-125	psychotic	_
1-17	126-135	disorders	_
1-18	136-137	,	_
1-19	138-141	and	_
1-20	142-145	may	_
1-21	146-153	reflect	_
1-22	154-164	underlying	_
1-23	165-180	pathophysiology	_
1-24	181-182	.	_

2-1	183-190	However	_
2-2	191-192	,	_
2-3	193-204	substantial	_
2-4	205-214	cognitive	_
2-5	215-228	heterogeneity	_
2-6	229-235	exists	_
2-7	236-240	both	_
2-8	241-247	within	_
2-9	248-251	and	_
2-10	252-259	between	_
2-11	260-270	diagnostic	_
2-12	271-281	categories	_
2-13	282-283	,	_
2-14	284-292	creating	_
2-15	293-303	challenges	_
2-16	304-307	for	_
2-17	308-316	studying	_
2-18	317-320	the	_
2-19	321-333	neurobiology	_
2-20	334-336	of	_
2-21	337-346	cognitive	_
2-22	347-358	dysfunction	_
2-23	359-361	in	_
2-24	362-370	patients	_
2-25	371-372	.	_

3-1	373-376	The	_
3-2	377-380	aim	_
3-3	381-383	of	_
3-4	384-388	this	_
3-5	389-394	study	_
3-6	395-398	was	_
3-7	399-401	to	_
3-8	402-410	identify	_
3-9	411-419	patients	_
3-10	420-424	with	_
3-11	425-434	psychosis	_
3-12	435-439	with	_
3-13	440-446	intact	_
3-14	447-453	versus	_
3-15	454-462	impaired	_
3-16	463-472	cognitive	_
3-17	473-481	profiles	_
3-18	482-483	,	_
3-19	484-487	and	_
3-20	488-490	to	_
3-21	491-498	examine	_
3-22	499-506	resting	_
3-23	507-512	state	_
3-24	513-523	functional	_
3-25	524-536	connectivity	_
3-26	537-544	between	_
3-27	545-552	patient	_
3-28	553-559	groups	_
3-29	560-563	and	_
3-30	564-572	compared	_
3-31	573-575	to	_
3-32	576-583	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-33	584-592	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-34	593-595	to	_
3-35	596-605	determine	_
3-36	606-609	the	_
3-37	610-616	extent	_
3-38	617-619	to	_
3-39	620-625	which	_
3-40	626-634	patterns	_
3-41	635-637	of	_
3-42	638-650	connectivity	_
3-43	651-654	are	_
3-44	655-666	overlapping	_
3-45	667-669	or	_
3-46	670-678	distinct	_
3-47	679-680	.	_

4-1	681-688	Methods	_
4-2	689-690	:	_
4-3	691-703	Participants	_
4-4	704-708	with	_
4-5	709-718	affective	_
4-6	719-721	or	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
4-7	722-735	non-affective	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
4-8	736-745	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
4-9	746-747	(	_
4-10	748-753	n=120	_
4-11	754-755	)	_
4-12	756-759	and	_
4-13	760-767	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-14	768-776	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-15	777-778	(	_
4-16	779-783	n=31	_
4-17	784-785	)	_
4-18	786-790	were	_
4-19	791-803	administered	_
4-20	804-807	the	_
4-21	808-815	MATRICS	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest
4-22	816-825	Consensus	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest
4-23	826-835	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest
4-24	836-843	Battery	http://maven.renci.org/NeuroBridge/neurobridge#NeurocognitiveTest
4-25	844-845	,	_
4-26	846-854	clinical	_
4-27	855-858	and	_
4-28	859-868	community	_
4-29	869-880	functioning	_
4-30	881-892	assessments	_
4-31	893-894	,	_
4-32	895-898	and	_
4-33	899-901	an	_
4-34	902-906	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
4-35	907-911	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
4-36	912-914	to	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
4-37	915-922	measure	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
4-38	923-930	resting	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-39	931-936	state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-40	937-947	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-41	948-960	connectivity	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-42	961-962	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-43	963-967	RSFC	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-44	968-969	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
4-45	970-971	.	_

5-1	972-981	Cognitive	_
5-2	982-991	composite	_
5-3	992-998	scores	_
5-4	999-1003	were	_
5-5	1004-1008	used	_
5-6	1009-1011	to	_
5-7	1012-1020	identify	_
5-8	1021-1027	groups	_
5-9	1028-1030	of	_
5-10	1031-1039	patients	_
5-11	1040-1044	with	_
5-12	1045-1048	and	_
5-13	1049-1056	without	_
5-14	1057-1066	cognitive	_
5-15	1067-1078	dysfunction	_
5-16	1079-1080	.	_

6-1	1081-1085	RSFC	_
6-2	1086-1089	was	_
6-3	1090-1098	compared	_
6-4	1099-1106	between	_
6-5	1107-1113	groups	_
6-6	1114-1116	of	_
6-7	1117-1125	patients	_
6-8	1126-1129	and	_
6-9	1130-1137	healthy	_
6-10	1138-1146	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-11	1147-1148	,	_
6-12	1149-1160	controlling	_
6-13	1161-1164	for	_
6-14	1165-1176	demographic	_
6-15	1177-1180	and	_
6-16	1181-1189	clinical	_
6-17	1190-1199	variables	_
6-18	1200-1201	.	_

7-1	1202-1209	Results	_
7-2	1210-1211	:	_
7-3	1212-1216	Both	_
7-4	1217-1228	cognitively	_
7-5	1229-1235	intact	_
7-6	1236-1239	and	_
7-7	1240-1251	cognitively	_
7-8	1252-1260	impaired	_
7-9	1261-1269	patients	_
7-10	1270-1276	showed	_
7-11	1277-1286	decreased	_
7-12	1287-1296	intrinsic	_
7-13	1297-1309	connectivity	_
7-14	1310-1318	compared	_
7-15	1319-1321	to	_
7-16	1322-1330	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-17	1331-1333	in	_
7-18	1334-1348	frontoparietal	_
7-19	1349-1356	control	_
7-20	1357-1358	(	_
7-21	1359-1362	FPN	_
7-22	1363-1364	)	_
7-23	1365-1368	and	_
7-24	1369-1374	motor	_
7-25	1375-1383	networks	_
7-26	1384-1385	.	_

8-1	1386-1394	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-2	1395-1399	with	_
8-3	1400-1409	cognitive	_
8-4	1410-1420	impairment	_
8-5	1421-1427	showed	_
8-6	1428-1438	additional	_
8-7	1439-1449	reductions	_
8-8	1450-1452	in	_
8-9	1453-1456	FPN	_
8-10	1457-1469	connectivity	_
8-11	1470-1478	compared	_
8-12	1479-1481	to	_
8-13	1482-1490	patients	_
8-14	1491-1495	with	_
8-15	1496-1502	intact	_
8-16	1503-1512	cognition	_
8-17	1513-1514	,	_
8-18	1515-1527	particularly	_
8-19	1528-1530	in	_
8-20	1531-1541	subnetwork	_
8-21	1542-1543	A	_
8-22	1544-1545	.	_

9-1	1546-1557	Conclusions	_
9-2	1558-1559	:	_
9-3	1560-1562	We	_
9-4	1563-1572	leveraged	_
9-5	1573-1576	the	_
9-6	1577-1590	heterogeneity	_
9-7	1591-1593	in	_
9-8	1594-1603	cognitive	_
9-9	1604-1611	ability	_
9-10	1612-1617	among	_
9-11	1618-1626	patients	_
9-12	1627-1631	with	_
9-13	1632-1641	psychosis	_
9-14	1642-1644	to	_
9-15	1645-1656	disentangle	_
9-16	1657-1660	the	_
9-17	1661-1669	relative	_
9-18	1670-1683	contributions	_
9-19	1684-1686	of	_
9-20	1687-1696	cognitive	_
9-21	1697-1708	dysfunction	_
9-22	1709-1712	and	_
9-23	1713-1721	presence	_
9-24	1722-1724	of	_
9-25	1725-1727	an	_
9-26	1728-1738	underlying	_
9-27	1739-1748	psychotic	_
9-28	1749-1756	illness	_
9-29	1757-1762	using	_
9-30	1763-1770	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
9-31	1771-1776	state	_
9-32	1777-1787	functional	_
9-33	1788-1800	connectivity	_
9-34	1801-1802	.	_

10-1	1803-1808	These	_
10-2	1809-1817	findings	_
10-3	1818-1825	suggest	_
10-4	1826-1828	at	_
10-5	1829-1834	least	_
10-6	1835-1844	partially	_
10-7	1845-1854	separable	_
10-8	1855-1862	effects	_
10-9	1863-1865	of	_
10-10	1866-1874	presence	_
10-11	1875-1877	of	_
10-12	1878-1879	a	_
10-13	1880-1889	psychotic	_
10-14	1890-1898	disorder	_
10-15	1899-1902	and	_
10-16	1903-1917	neurocognitive	_
10-17	1918-1928	impairment	_
10-18	1929-1941	contributing	_
10-19	1942-1944	to	_
10-20	1945-1952	network	_
10-21	1953-1968	dysconnectivity	_
10-22	1969-1971	in	_
10-23	1972-1981	psychosis	_
10-24	1982-1983	.	_

11-1	1984-1993	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-2	1994-1997	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-3	1998-2007	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
11-4	2008-2020	Participants	_
11-5	2021-2033	Participants	_
11-6	2034-2038	with	_
11-7	2039-2048	diagnoses	_
11-8	2049-2051	of	_
11-9	2052-2061	affective	_
11-10	2062-2064	or	_
11-11	2065-2078	non-affective	_
11-12	2079-2088	psychosis	_
11-13	2089-2090	(	_
11-14	2091-2096	n=120	_
11-15	2097-2098	)	_
11-16	2099-2102	and	_
11-17	2103-2110	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-18	2111-2119	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-19	2120-2121	(	_
11-20	2122-2126	n=31	_
11-21	2127-2128	)	_
11-22	2129-2133	were	_
11-23	2134-2143	recruited	_
11-24	2144-2151	through	_
11-25	2152-2155	the	_
11-26	2156-2169	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
11-27	2170-2173	and	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
11-28	2174-2181	Bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
11-29	2182-2190	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
11-30	2191-2198	Program	_
11-31	2199-2200	(	_
11-32	2201-2205	SBDP	http://maven.renci.org/NeuroBridge/neurobridge#Thing
11-33	2206-2207	)	_
11-34	2208-2211	and	_
11-35	2212-2215	via	_
11-36	2216-2222	fliers	_
11-37	2223-2229	posted	_
11-38	2230-2232	at	_
11-39	2233-2239	McLean	_
11-40	2240-2248	Hospital	_
11-41	2249-2250	.	_

12-1	2251-2263	Participants	_
12-2	2264-2268	were	_
12-3	2269-2278	recruited	_
12-4	2279-2281	in	_
12-5	2282-2285	the	_
12-6	2286-2293	context	_
12-7	2294-2296	of	_
12-8	2297-2304	several	_
12-9	2305-2313	separate	_
12-10	2314-2317	but	_
12-11	2318-2325	related	_
12-12	2326-2333	studies	_
12-13	2334-2335	:	_
12-14	2336-2337	1	_
12-15	2338-2339	)	_
12-16	2340-2349	cognitive	_
12-17	2350-2361	remediation	_
12-18	2362-2364	in	_
12-19	2365-2367	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
12-20	2368-2370	or	_
12-21	2371-2378	Bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
12-22	2379-2387	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
12-23	2388-2389	(	_
12-24	2390-2392	BD	_
12-25	2393-2394	)	_
12-26	2395-2396	(	_
12-27	2397-2399	n=	_
12-28	2400-2402	42	_
12-29	2403-2404	)	_
12-30	2405-2406	,	_
12-31	2407-2408	2	_
12-32	2409-2410	)	_
12-33	2411-2423	neuroimaging	_
12-34	2424-2425	(	_
12-35	2426-2430	n=33	_
12-36	2431-2432	)	_
12-37	2433-2434	,	_
12-38	2435-2437	or	_
12-39	2438-2439	3	_
12-40	2440-2441	)	_
12-41	2442-2450	clinical	_
12-42	2451-2467	characterization	_
12-43	2468-2470	of	_
12-44	2471-2480	psychosis	_
12-45	2481-2482	(	_
12-46	2483-2487	n=76	_
12-47	2488-2489	)	_
12-48	2490-2491	.	_

13-1	2492-2495	For	_
13-2	2496-2504	subjects	_
13-3	2505-2508	who	_
13-4	2509-2521	participated	_
13-5	2522-2524	in	_
13-6	2525-2528	one	_
13-7	2529-2531	of	_
13-8	2532-2535	the	_
13-9	2536-2545	cognitive	_
13-10	2546-2557	remediation	_
13-11	2558-2570	intervention	_
13-12	2571-2578	studies	_
13-13	2579-2580	,	_
13-14	2581-2589	baseline	_
13-15	2590-2599	cognitive	_
13-16	2600-2603	and	_
13-17	2604-2611	imaging	_
13-18	2612-2616	data	_
13-19	2617-2621	were	_
13-20	2622-2626	used	_
13-21	2627-2628	.	_

14-1	2629-2638	Inclusion	_
14-2	2639-2647	criteria	_
14-3	2648-2656	included	_
14-4	2657-2658	a	_
14-5	2659-2665	DSM-IV	_
14-6	2666-2675	diagnosis	_
14-7	2676-2678	of	_
14-8	2679-2681	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
14-9	2682-2683	,	_
14-10	2684-2699	Schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-11	2700-2708	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-12	2709-2710	(	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-13	2711-2714	SZA	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-14	2715-2716	)	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-15	2717-2718	,	_
14-16	2719-2735	Schizophreniform	http://maven.renci.org/NeuroBridge/neurobridge#SchizophreniformDisorder
14-17	2736-2744	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#SchizophreniformDisorder
14-18	2745-2746	,	_
14-19	2747-2756	Psychosis	_
14-20	2757-2760	NOS	_
14-21	2761-2762	,	_
14-22	2763-2765	BD	http://maven.renci.org/NeuroBridge/neurobridge#Type1DiabetesMellitus
14-23	2766-2767	I	http://maven.renci.org/NeuroBridge/neurobridge#Type1DiabetesMellitus
14-24	2768-2772	with	_
14-25	2773-2782	psychosis	_
14-26	2783-2784	,	_
14-27	2785-2787	or	_
14-28	2788-2791	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
14-29	2792-2796	with	_
14-30	2797-2806	psychosis	_
14-31	2807-2808	,	_
14-32	2809-2813	ages	_
14-33	2814-2816	18	_
14-34	2817-2819	to	_
14-35	2820-2822	65	_
14-36	2823-2824	.	_

15-1	2825-2834	Exclusion	_
15-2	2835-2843	criteria	_
15-3	2844-2847	for	_
15-4	2848-2851	all	_
15-5	2852-2864	participants	_
15-6	2865-2873	included	_
15-7	2874-2881	history	_
15-8	2882-2884	of	_
15-9	2885-2889	head	_
15-10	2890-2896	trauma	_
15-11	2897-2901	with	_
15-12	2902-2906	loss	_
15-13	2907-2909	of	_
15-14	2910-2923	consciousness	_
15-15	2924-2925	,	_
15-16	2926-2933	history	_
15-17	2934-2936	of	_
15-18	2937-2944	seizure	_
15-19	2945-2946	,	_
15-20	2947-2950	and	_
15-21	2951-2958	current	_
15-22	2959-2968	substance	_
15-23	2969-2974	abuse	_
15-24	2975-2977	or	_
15-25	2978-2988	dependence	_
15-26	2989-2990	.	_

16-1	2991-2998	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-2	2999-3007	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-3	3008-3011	had	_
16-4	3012-3014	no	_
16-5	3015-3023	personal	_
16-6	3024-3026	or	_
16-7	3027-3039	first-degree	_
16-8	3040-3046	family	_
16-9	3047-3054	history	_
16-10	3055-3057	of	_
16-11	3058-3059	a	_
16-12	3060-3071	psychiatric	_
16-13	3072-3081	diagnosis	_
16-14	3082-3083	,	_
16-15	3084-3087	and	_
16-16	3088-3090	no	_
16-17	3091-3098	history	_
16-18	3099-3101	of	_
16-19	3102-3111	substance	_
16-20	3112-3117	abuse	_
16-21	3118-3120	or	_
16-22	3121-3131	dependence	_
16-23	3132-3133	.	_

17-1	3134-3137	All	_
17-2	3138-3148	procedures	_
17-3	3149-3153	were	_
17-4	3154-3162	approved	_
17-5	3163-3165	by	_
17-6	3166-3169	the	_
17-7	3170-3176	McLean	_
17-8	3177-3185	Hospital	_
17-9	3186-3189	IRB	_
17-10	3190-3191	.	_

18-1	3192-3201	Materials	_
18-2	3202-3211	Diagnosis	_
18-3	3212-3215	was	_
18-4	3216-3226	determined	_
18-5	3227-3232	using	_
18-6	3233-3236	the	_
18-7	3237-3247	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-8	3248-3256	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-9	3257-3266	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-10	3267-3270	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-11	3271-3277	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-12	3278-3279	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-13	3280-3290	SCID-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-14	3291-3292	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
18-15	3293-3300	through	_
18-16	3301-3308	patient	_
18-17	3309-3318	interview	_
18-18	3319-3320	,	_
18-19	3321-3328	medical	_
18-20	3329-3335	record	_
18-21	3336-3342	review	_
18-22	3343-3344	,	_
18-23	3345-3348	and	_
18-24	3349-3361	consultation	_
18-25	3362-3366	with	_
18-26	3367-3370	the	_
18-27	3371-3383	participants	_
18-28	3384-3385	’	_
18-29	3386-3395	treatment	_
18-30	3396-3405	providers	_
18-31	3406-3407	.	_

19-1	3408-3416	Clinical	_
19-2	3417-3427	assessment	_
19-3	3428-3436	included	_
19-4	3437-3440	the	_
19-5	3441-3446	Young	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
19-6	3447-3452	Mania	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
19-7	3453-3459	Rating	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
19-8	3460-3465	Scale	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
19-9	3466-3467	(	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
19-10	3468-3472	YMRS	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
19-11	3473-3474	)	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
19-12	3475-3476	,	_
19-13	3477-3480	the	_
19-14	3481-3498	Montgomery-Asberg	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
19-15	3499-3509	Depression	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
19-16	3510-3516	Rating	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
19-17	3517-3522	Scale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
19-18	3523-3524	(	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
19-19	3525-3530	MADRS	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
19-20	3531-3532	)	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
19-21	3533-3534	,	_
19-22	3535-3538	and	_
19-23	3539-3542	the	_
19-24	3543-3551	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-25	3552-3555	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-26	3556-3564	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-27	3565-3573	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-28	3574-3579	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-29	3580-3581	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-30	3582-3587	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-31	3588-3589	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
19-32	3590-3591	.	_

20-1	3592-3601	Community	_
20-2	3602-3613	functioning	_
20-3	3614-3617	was	_
20-4	3618-3626	measured	_
20-5	3627-3632	using	_
20-6	3633-3635	an	_
20-7	3636-3647	abbreviated	_
20-8	3648-3655	version	_
20-9	3656-3658	of	_
20-10	3659-3662	the	_
20-11	3663-3672	Multnomah	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsivityScale
20-12	3673-3682	Community	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsivityScale
20-13	3683-3690	Ability	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsivityScale
20-14	3691-3696	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsivityScale
20-15	3697-3698	(	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsivityScale
20-16	3699-3703	MCAS	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsivityScale
20-17	3704-3705	)	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsivityScale
20-18	3706-3707	,	_
20-19	3708-3710	as	_
20-20	3711-3720	described	_
20-21	3721-3723	by	_
20-22	3724-3735	Lewandowski	_
20-23	3736-3738	et	_
20-24	3739-3741	al	_
20-25	3742-3744	..	_
20-26	3745-3754	Premorbid	_
20-27	3755-3757	IQ	_
20-28	3758-3761	was	_
20-29	3762-3770	measured	_
20-30	3771-3775	with	_
20-31	3776-3779	the	_
20-32	3780-3785	North	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
20-33	3786-3794	American	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
20-34	3795-3800	Adult	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
20-35	3801-3808	Reading	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
20-36	3809-3813	Test	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
20-37	3814-3815	(	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
20-38	3816-3821	NAART	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
20-39	3822-3823	)	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
20-40	3824-3825	.	_

21-1	3826-3835	Cognition	_
21-2	3836-3839	was	_
21-3	3840-3848	measured	_
21-4	3849-3854	using	_
21-5	3855-3858	the	_
21-6	3859-3866	MATRICS	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
21-7	3867-3876	Consensus	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
21-8	3877-3886	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
21-9	3887-3894	Battery	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
21-10	3895-3896	(	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
21-11	3897-3901	MCCB	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
21-12	3902-3903	)	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
21-13	3904-3905	.	_

22-1	3906-3909	The	_
22-2	3910-3914	MCCB	_
22-3	3915-3917	is	_
22-4	3918-3927	comprised	_
22-5	3928-3930	of	_
22-6	3931-3934	ten	_
22-7	3935-3943	subtests	_
22-8	3944-3948	that	_
22-9	3949-3953	make	_
22-10	3954-3956	up	_
22-11	3957-3962	seven	_
22-12	3963-3969	domain	_
22-13	3970-3976	scores	_
22-14	3977-3980	and	_
22-15	3981-3982	a	_
22-16	3983-3992	composite	_
22-17	3993-3994	.	_

23-1	3995-4002	Domains	_
23-2	4003-4010	include	_
23-3	4011-4012	:	_
23-4	4013-4018	Speed	_
23-5	4019-4021	of	_
23-6	4022-4032	Processing	_
23-7	4033-4034	(	_
23-8	4035-4040	Trail	_
23-9	4041-4047	Making	_
23-10	4048-4052	Test	_
23-11	4053-4054	A	_
23-12	4055-4056	;	_
23-13	4057-4062	Brief	_
23-14	4063-4073	Assessment	_
23-15	4074-4076	of	_
23-16	4077-4086	Cognition	_
23-17	4087-4089	in	_
23-18	4090-4103	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
23-19	4104-4105	:	_
23-20	4106-4112	Symbol	_
23-21	4113-4119	Coding	_
23-22	4120-4121	;	_
23-23	4122-4130	Category	_
23-24	4131-4138	Fluency	_
23-25	4139-4140	)	_
23-26	4141-4142	;	_
23-27	4143-4162	Attention/Vigilance	_
23-28	4163-4164	(	_
23-29	4165-4175	Continuous	_
23-30	4176-4187	Performance	_
23-31	4188-4192	Test	http://maven.renci.org/NeuroBridge/neurobridge#GlucoseToleranceTest
23-32	4193-4194	:	_
23-33	4195-4204	Identical	_
23-34	4205-4210	Pairs	_
23-35	4211-4212	)	_
23-36	4213-4214	;	_
23-37	4215-4222	Working	_
23-38	4223-4229	Memory	_
23-39	4230-4231	(	_
23-40	4232-4240	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-41	4241-4247	Memory	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-42	4248-4253	Scale	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-43	4254-4261	Spatial	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-44	4262-4266	Span	http://maven.renci.org/NeuroBridge/neurobridge#SpatialWorkingMemory
23-45	4267-4268	;	_
23-46	4269-4275	Letter	_
23-47	4276-4282	Number	_
23-48	4283-4287	Span	_
23-49	4288-4289	)	_
23-50	4290-4291	;	_
23-51	4292-4298	Visual	_
23-52	4299-4307	Learning	_
23-53	4308-4309	(	_
23-54	4310-4315	Brief	_
23-55	4316-4328	Visuospatial	_
23-56	4329-4335	Memory	_
23-57	4336-4340	Test	_
23-58	4341-4342	)	_
23-59	4343-4344	;	_
23-60	4345-4351	Verbal	_
23-61	4352-4360	Learning	_
23-62	4361-4362	(	_
23-63	4363-4370	Hopkins	_
23-64	4371-4377	Verbal	_
23-65	4378-4386	Learning	_
23-66	4387-4391	Test	_
23-67	4392-4393	)	_
23-68	4394-4395	;	_
23-69	4396-4413	Reasoning/Problem	_
23-70	4414-4421	Solving	http://maven.renci.org/NeuroBridge/neurobridge#Thing
23-71	4422-4423	(	_
23-72	4424-4442	Neuropsychological	_
23-73	4443-4453	Assessment	_
23-74	4454-4461	Battery	_
23-75	4462-4463	:	_
23-76	4464-4469	Mazes	_
23-77	4470-4471	)	_
23-78	4472-4473	;	_
23-79	4474-4477	and	_
23-80	4478-4484	Social	_
23-81	4485-4494	Cognition	_
23-82	4495-4496	(	_
23-83	4497-4517	Mayer-Salovey-Caruso	_
23-84	4518-4527	Emotional	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
23-85	4528-4540	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
23-86	4541-4545	Test	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
23-87	4546-4547	:	_
23-88	4548-4556	Managing	_
23-89	4557-4565	Emotions	_
23-90	4566-4567	)	_
23-91	4568-4569	.	_

24-1	4570-4577	Subtest	_
24-2	4578-4579	,	_
24-3	4580-4586	domain	_
24-4	4587-4588	,	_
24-5	4589-4592	and	_
24-6	4593-4602	composite	_
24-7	4603-4609	scores	_
24-8	4610-4613	are	_
24-9	4614-4623	converted	_
24-10	4624-4626	to	_
24-11	4627-4635	T-scores	_
24-12	4636-4641	based	_
24-13	4642-4644	on	_
24-14	4645-4649	MCCB	_
24-15	4650-4653	age	_
24-16	4654-4657	and	_
24-17	4658-4664	gender	_
24-18	4665-4673	adjusted	_
24-19	4674-4679	norms	_
24-20	4680-4681	.	_

25-1	4682-4685	The	_
25-2	4686-4690	MCCB	_
25-3	4691-4696	takes	_
25-4	4697-4710	approximately	_
25-5	4711-4716	60-90	_
25-6	4717-4724	minutes	_
25-7	4725-4727	to	_
25-8	4728-4736	complete	_
25-9	4737-4738	.	_

26-1	4739-4744	Image	_
26-2	4745-4756	Acquisition	_
26-3	4757-4764	Details	_
26-4	4765-4767	of	_
26-5	4768-4773	image	_
26-6	4774-4785	acquisition	_
26-7	4786-4789	for	_
26-8	4790-4793	the	_
26-9	4794-4802	majority	_
26-10	4803-4805	of	_
26-11	4806-4818	participants	_
26-12	4819-4823	have	_
26-13	4824-4828	been	_
26-14	4829-4838	described	_
26-15	4839-4849	previously	_
26-16	4850-4851	.	_

27-1	4852-4859	Briefly	_
27-2	4860-4861	,	_
27-3	4862-4866	data	_
27-4	4867-4871	were	_
27-5	4872-4880	acquired	_
27-6	4881-4886	using	_
27-7	4887-4888	a	_
27-8	4889-4896	Siemens	_
27-9	4897-4899	3T	_
27-10	4900-4903	Tim	_
27-11	4904-4908	Trio	_
27-12	4909-4916	scanner	_
27-13	4917-4921	with	_
27-14	4922-4923	a	_
27-15	4924-4934	12-channel	_
27-16	4935-4947	phased-array	_
27-17	4948-4952	head	_
27-18	4953-4957	coil	_
27-19	4958-4959	.	_

28-1	4960-4975	High-resolution	_
28-2	4976-4977	,	_
28-3	4978-4989	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
28-4	4990-4991	,	_
28-5	4992-5001	multiecho	_
28-6	5002-5003	,	_
28-7	5004-5026	magnetization-prepared	_
28-8	5027-5028	,	_
28-9	5029-5042	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
28-10	5043-5053	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
28-11	5054-5060	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
28-12	5061-5065	were	_
28-13	5066-5075	collected	_
28-14	5076-5077	.	_

29-1	5078-5088	Functional	_
29-2	5089-5093	data	_
29-3	5094-5098	were	_
29-4	5099-5108	collected	_
29-5	5109-5113	with	_
29-6	5114-5115	a	_
29-7	5116-5129	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
29-8	5130-5134	echo	_
29-9	5135-5141	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-10	5142-5149	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-11	5150-5158	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
29-12	5159-5161	to	_
29-13	5162-5168	detect	_
29-14	5169-5174	blood	_
29-15	5175-5186	oxygenation	_
29-16	5187-5202	level-dependent	_
29-17	5203-5204	(	_
29-18	5205-5209	BOLD	_
29-19	5210-5211	)	_
29-20	5212-5220	contrast	_
29-21	5221-5222	.	_

30-1	5223-5227	BOLD	_
30-2	5228-5239	acquisition	_
30-3	5240-5250	parameters	_
30-4	5251-5254	for	_
30-5	5255-5258	the	_
30-6	5259-5264	three	_
30-7	5265-5274	protocols	_
30-8	5275-5283	combined	_
30-9	5284-5286	in	_
30-10	5287-5291	this	_
30-11	5292-5300	analysis	_
30-12	5301-5305	were	_
30-13	5306-5308	as	_
30-14	5309-5316	follows	_
30-15	5317-5318	:	_
30-16	5319-5320	(	_
30-17	5321-5322	1	_
30-18	5323-5324	)	_
30-19	5325-5327	TR	_
30-20	5328-5329	=	_
30-21	5330-5336	3000ms	_
30-22	5337-5338	,	_
30-23	5339-5341	TE	_
30-24	5342-5343	=	_
30-25	5344-5348	30ms	_
30-26	5349-5350	,	_
30-27	5351-5355	flip	_
30-28	5356-5361	angle	_
30-29	5362-5363	=	_
30-30	5364-5367	85°	_
30-31	5368-5369	,	_
30-32	5370-5377	3×3×3mm	_
30-33	5378-5384	voxels	_
30-34	5385-5386	,	_
30-35	5387-5392	72×72	_
30-36	5393-5399	matrix	_
30-37	5400-5401	,	_
30-38	5402-5405	FOV	_
30-39	5406-5407	=	_
30-40	5408-5413	216mm	_
30-41	5414-5415	,	_
30-42	5416-5418	47	_
30-43	5419-5430	interleaved	_
30-44	5431-5436	axial	_
30-45	5437-5443	slices	_
30-46	5444-5448	with	_
30-47	5449-5451	no	_
30-48	5452-5455	gap	_
30-49	5456-5457	,	_
30-50	5458-5461	and	_
30-51	5462-5470	duration	_
30-52	5471-5472	=	_
30-53	5473-5476	6.2	_
30-54	5477-5484	minutes	_
30-55	5485-5486	(	_
30-56	5487-5490	124	_
30-57	5491-5495	time	_
30-58	5496-5502	points	_
30-59	5503-5504	)	_
30-60	5505-5506	;	_
30-61	5507-5508	(	_
30-62	5509-5510	2	_
30-63	5511-5512	)	_
30-64	5513-5515	TR	_
30-65	5516-5517	=	_
30-66	5518-5524	2500ms	_
30-67	5525-5526	,	_
30-68	5527-5529	TE	_
30-69	5530-5531	=	_
30-70	5532-5536	24ms	_
30-71	5537-5538	;	_
30-72	5539-5543	flip	_
30-73	5544-5549	angle	_
30-74	5550-5551	=	_
30-75	5552-5555	82°	_
30-76	5556-5557	,	_
30-77	5558-5571	3.5×3.5×3.5mm	_
30-78	5572-5578	voxels	_
30-79	5579-5580	,	_
30-80	5581-5586	64×64	_
30-81	5587-5593	matrix	_
30-82	5594-5595	,	_
30-83	5596-5599	FOV	_
30-84	5600-5601	=	_
30-85	5602-5607	224mm	_
30-86	5608-5609	,	_
30-87	5610-5612	42	_
30-88	5613-5618	axial	_
30-89	5619-5625	slices	_
30-90	5626-5627	,	_
30-91	5628-5631	and	_
30-92	5632-5640	duration	_
30-93	5641-5642	=	_
30-94	5643-5645	10	_
30-95	5646-5653	minutes	_
30-96	5654-5655	(	_
30-97	5656-5659	240	_
30-98	5660-5664	time	_
30-99	5665-5671	points	_
30-100	5672-5673	)	_
30-101	5674-5675	;	_
30-102	5676-5679	and	_
30-103	5680-5681	(	_
30-104	5682-5683	3	_
30-105	5684-5685	)	_
30-106	5686-5688	TR	_
30-107	5689-5690	=	_
30-108	5691-5697	2500ms	_
30-109	5698-5699	,	_
30-110	5700-5702	TE	_
30-111	5703-5704	=	_
30-112	5705-5709	30ms	_
30-113	5710-5711	;	_
30-114	5712-5716	flip	_
30-115	5717-5722	angle	_
30-116	5723-5724	=	_
30-117	5725-5728	82°	_
30-118	5729-5730	,	_
30-119	5731-5744	3.5×3.5×3.5mm	_
30-120	5745-5751	voxels	_
30-121	5752-5753	,	_
30-122	5754-5759	64×64	_
30-123	5760-5766	matrix	_
30-124	5767-5768	,	_
30-125	5769-5772	FOV	_
30-126	5773-5774	=	_
30-127	5775-5780	224mm	_
30-128	5781-5782	,	_
30-129	5783-5785	41	_
30-130	5786-5791	axial	_
30-131	5792-5798	slices	_
30-132	5799-5800	,	_
30-133	5801-5804	and	_
30-134	5805-5813	duration	_
30-135	5814-5815	=	_
30-136	5816-5820	6.67	_
30-137	5821-5828	minutes	_
30-138	5829-5830	(	_
30-139	5831-5834	160	_
30-140	5835-5839	time	_
30-141	5840-5846	points	_
30-142	5847-5848	)	_
30-143	5849-5850	.	_

31-1	5851-5853	An	_
31-2	5854-5863	automated	_
31-3	5864-5873	alignment	_
31-4	5874-5883	procedure	_
31-5	5884-5892	aligning	_
31-6	5893-5898	whole	_
31-7	5899-5904	brain	_
31-8	5905-5913	coverage	_
31-9	5914-5916	to	_
31-10	5917-5920	the	_
31-11	5921-5929	anterior	_
31-12	5930-5950	commissure-posterior	_
31-13	5951-5961	commissure	_
31-14	5962-5965	was	_
31-15	5966-5970	used	_
31-16	5971-5974	for	_
31-17	5975-5986	consistency	_
31-18	5987-5993	across	_
31-19	5994-6006	participants	_
31-20	6007-6008	.	_

32-1	6009-6012	One	_
32-2	6013-6015	to	_
32-3	6016-6019	two	_
32-4	6020-6030	functional	_
32-5	6031-6036	scans	_
32-6	6037-6041	were	_
32-7	6042-6050	acquired	_
32-8	6051-6054	per	_
32-9	6055-6066	participant	_
32-10	6067-6068	,	_
32-11	6069-6072	and	_
32-12	6073-6075	we	_
32-13	6076-6084	assessed	_
32-14	6085-6089	mean	_
32-15	6090-6099	estimates	_
32-16	6100-6106	across	_
32-17	6107-6112	scans	_
32-18	6113-6115	in	_
32-19	6116-6119	the	_
32-20	6120-6124	case	_
32-21	6125-6127	of	_
32-22	6128-6131	two	_
32-23	6132-6144	acquisitions	_
32-24	6145-6146	.	_

33-1	6147-6156	Procedure	_
33-2	6157-6175	Neuropsychological	_
33-3	6176-6177	,	_
33-4	6178-6190	neuroimaging	_
33-5	6191-6192	,	_
33-6	6193-6196	and	_
33-7	6197-6207	diagnostic	_
33-8	6208-6212	data	_
33-9	6213-6217	were	_
33-10	6218-6227	collected	_
33-11	6228-6230	in	_
33-12	6231-6234	2–3	_
33-13	6235-6243	sessions	_
33-14	6244-6245	.	_

34-1	6246-6262	Patient-reported	_
34-2	6263-6274	information	_
34-3	6275-6284	regarding	_
34-4	6285-6295	medication	_
34-5	6296-6299	and	_
34-6	6300-6304	dose	_
34-7	6305-6308	was	_
34-8	6309-6318	collected	_
34-9	6319-6320	,	_
34-10	6321-6324	and	_
34-11	6325-6339	chlorpromazine	_
34-12	6340-6351	equivalents	_
34-13	6352-6353	(	_
34-14	6354-6357	CPZ	_
34-15	6358-6359	)	_
34-16	6360-6364	were	_
34-17	6365-6375	calculated	_
34-18	6376-6381	using	_
34-19	6382-6392	guidelines	_
34-20	6393-6402	described	_
34-21	6403-6405	by	_
34-22	6406-6418	Baldessarini	_
34-23	6419-6420	.	_

35-1	6421-6427	During	_
35-2	6428-6441	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
35-3	6442-6452	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
35-4	6453-6458	scans	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
35-5	6459-6460	,	_
35-6	6461-6473	participants	_
35-7	6474-6478	were	_
35-8	6479-6483	told	_
35-9	6484-6486	to	_
35-10	6487-6491	stay	_
35-11	6492-6497	awake	_
35-12	6498-6499	,	_
35-13	6500-6506	remain	_
35-14	6507-6512	still	_
35-15	6513-6514	,	_
35-16	6515-6519	keep	_
35-17	6520-6525	their	_
35-18	6526-6530	eyes	_
35-19	6531-6535	open	_
35-20	6536-6537	,	_
35-21	6538-6541	and	_
35-22	6542-6547	think	_
35-23	6548-6550	of	_
35-24	6551-6558	nothing	_
35-25	6559-6561	in	_
35-26	6562-6572	particular	_
35-27	6573-6574	;	_
35-28	6575-6577	no	_
35-29	6578-6586	fixation	_
35-30	6587-6593	marker	_
35-31	6594-6597	was	_
35-32	6598-6602	used	_
35-33	6603-6604	.	_

36-1	6605-6617	Participants	_
36-2	6618-6622	were	_
36-3	6623-6632	monitored	_
36-4	6633-6637	with	_
36-5	6638-6641	eye	_
36-6	6642-6650	tracking	_
36-7	6651-6653	to	_
36-8	6654-6660	ensure	_
36-9	6661-6665	that	_
36-10	6666-6670	eyes	_
36-11	6671-6679	remained	_
36-12	6680-6684	open	_
36-13	6685-6691	during	_
36-14	6692-6695	the	_
36-15	6696-6706	functional	_
36-16	6707-6711	scan	_
36-17	6712-6713	.	_

37-1	6714-6725	Statistical	_
37-2	6726-6734	Approach	_
37-3	6735-6744	Cognitive	_
37-4	6745-6754	groupings	_
37-5	6755-6759	were	_
37-6	6760-6770	determined	_
37-7	6771-6776	using	_
37-8	6777-6781	MCCB	_
37-9	6782-6791	Composite	_
37-10	6792-6798	scores	_
37-11	6799-6800	,	_
37-12	6801-6806	using	_
37-13	6807-6808	a	_
37-14	6809-6815	cutoff	_
37-15	6816-6818	of	_
37-16	6819-6823	MCCB	_
37-17	6824-6833	Composite	_
37-18	6834-6835	<	_
37-19	6836-6842	−1.0SD	_
37-20	6843-6845	to	_
37-21	6846-6852	define	_
37-22	6853-6854	a	_
37-23	6855-6860	group	_
37-24	6861-6874	characterized	_
37-25	6875-6877	by	_
37-26	6878-6886	impaired	_
37-27	6887-6905	neuropsychological	_
37-28	6906-6917	functioning	_
37-29	6918-6919	(	_
37-30	6920-6928	Impaired	_
37-31	6929-6930	)	_
37-32	6931-6932	,	_
37-33	6933-6936	and	_
37-34	6937-6941	MCCB	_
37-35	6942-6951	Composite	_
37-36	6952-6958	scores	_
37-37	6959-6961	of	_
37-38	6962-6963	>	_
37-39	6964-6971	/=−.5SD	_
37-40	6972-6974	to	_
37-41	6975-6981	define	_
37-42	6982-6983	a	_
37-43	6984-6989	group	_
37-44	6990-7003	characterized	_
37-45	7004-7006	by	_
37-46	7007-7013	intact	_
37-47	7014-7032	neuropsychological	_
37-48	7033-7044	functioning	_
37-49	7045-7046	(	_
37-50	7047-7053	Intact	_
37-51	7054-7055	)	_
37-52	7056-7057	.	_

38-1	7058-7065	Similar	_
38-2	7066-7076	strategies	_
38-3	7077-7081	have	_
38-4	7082-7086	been	_
38-5	7087-7091	used	_
38-6	7092-7094	in	_
38-7	7095-7103	previous	_
38-8	7104-7111	reports	_
38-9	7112-7114	to	_
38-10	7115-7123	identify	_
38-11	7124-7128	more	_
38-12	7129-7140	homogeneous	_
38-13	7141-7147	groups	_
38-14	7148-7150	of	_
38-15	7151-7159	patients	_
38-16	7160-7165	based	_
38-17	7166-7168	on	_
38-18	7169-7178	cognition	_
38-19	7179-7180	.	_

39-1	7181-7185	This	_
39-2	7186-7194	approach	_
39-3	7195-7198	was	_
39-4	7199-7207	selected	_
39-5	7208-7209	a	_
39-6	7210-7211	)	_
39-7	7212-7214	to	_
39-8	7215-7221	create	_
39-9	7222-7228	groups	_
39-10	7229-7233	that	_
39-11	7234-7238	were	_
39-12	7239-7247	distinct	_
39-13	7248-7252	from	_
39-14	7253-7257	each	_
39-15	7258-7263	other	_
39-16	7264-7265	,	_
39-17	7266-7269	and	_
39-18	7270-7271	b	_
39-19	7272-7273	)	_
39-20	7274-7281	because	_
39-21	7282-7291	cognitive	_
39-22	7292-7298	scores	_
39-23	7299-7305	within	_
39-24	7306-7310	.5SD	_
39-25	7311-7313	of	_
39-26	7314-7317	the	_
39-27	7318-7322	mean	_
39-28	7323-7326	are	_
39-29	7327-7336	generally	_
39-30	7337-7347	considered	_
39-31	7348-7350	to	_
39-32	7351-7353	be	_
39-33	7354-7360	within	_
39-34	7361-7364	the	_
39-35	7365-7371	normal	_
39-36	7372-7377	range	_
39-37	7378-7385	whereas	_
39-38	7386-7392	scores	_
39-39	7393-7394	<	_
39-40	7395-7400	1.0SD	_
39-41	7401-7406	below	_
39-42	7407-7410	the	_
39-43	7411-7415	mean	_
39-44	7416-7419	are	_
39-45	7420-7429	generally	_
39-46	7430-7440	considered	_
39-47	7441-7449	impaired	_
39-48	7450-7451	,	_
39-49	7452-7459	thereby	_
39-50	7460-7468	creating	_
39-51	7469-7481	conceptually	_
39-52	7482-7492	meaningful	_
39-53	7493-7502	groupings	_
39-54	7503-7504	.	_

40-1	7505-7511	Groups	_
40-2	7512-7516	were	_
40-3	7517-7525	compared	_
40-4	7526-7528	on	_
40-5	7529-7532	all	_
40-6	7533-7537	MCCB	_
40-7	7538-7545	domains	_
40-8	7546-7552	scores	_
40-9	7553-7558	using	_
40-10	7559-7564	ANOVA	_
40-11	7565-7566	;	_
40-12	7567-7575	T-scores	_
40-13	7576-7580	were	_
40-14	7581-7589	reported	_
40-15	7590-7593	for	_
40-16	7594-7597	all	_
40-17	7598-7602	MCCB	_
40-18	7603-7612	variables	_
40-19	7613-7614	.	_

41-1	7615-7621	Groups	_
41-2	7622-7626	were	_
41-3	7627-7631	also	_
41-4	7632-7640	compared	_
41-5	7641-7643	on	_
41-6	7644-7655	demographic	_
41-7	7656-7659	and	_
41-8	7660-7668	clinical	_
41-9	7669-7678	variables	_
41-10	7679-7684	using	_
41-11	7685-7690	ANOVA	_
41-12	7691-7693	or	_
41-13	7694-7698	Chi2	_
41-14	7699-7701	as	_
41-15	7702-7713	appropriate	_
41-16	7714-7715	.	_

42-1	7716-7724	Post-hoc	_
42-2	7725-7731	paired	_
42-3	7732-7739	t-tests	_
42-4	7740-7744	were	_
42-5	7745-7754	conducted	_
42-6	7755-7758	for	_
42-7	7759-7762	all	_
42-8	7763-7774	significant	_
42-9	7775-7780	ANOVA	_
42-10	7781-7788	effects	_
42-11	7789-7790	.	_

43-1	7791-7794	All	_
43-2	7795-7800	group	_
43-3	7801-7812	comparisons	_
43-4	7813-7815	of	_
43-5	7816-7826	behavioral	_
43-6	7827-7831	data	_
43-7	7832-7836	were	_
43-8	7837-7846	conducted	_
43-9	7847-7852	using	_
43-10	7853-7863	Bonferroni	_
43-11	7864-7874	correction	_
43-12	7875-7878	for	_
43-13	7879-7887	multiple	_
43-14	7888-7899	comparisons	_
43-15	7900-7901	.	_

44-1	7902-7905	The	_
44-2	7906-7918	neuroimaging	_
44-3	7919-7927	analytic	_
44-4	7928-7936	approach	_
44-5	7937-7940	has	_
44-6	7941-7945	been	_
44-7	7946-7955	described	_
44-8	7956-7966	previously	_
44-9	7967-7968	.	_

45-1	7969-7976	Briefly	_
45-2	7977-7978	,	_
45-3	7979-7986	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
45-4	7987-7992	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
45-5	7993-7997	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
45-6	7998-8002	data	_
45-7	8003-8007	were	_
45-8	8008-8020	preprocessed	_
45-9	8021-8024	for	_
45-10	8025-8030	fcMRI	_
45-11	8031-8039	analysis	_
45-12	8040-8043	and	_
45-13	8044-8054	temporally	_
45-14	8055-8063	filtered	_
45-15	8064-8066	to	_
45-16	8067-8073	retain	_
45-17	8074-8085	frequencies	_
45-18	8086-8091	below	_
45-19	8092-8096	0.08	_
45-20	8097-8099	Hz	_
45-21	8100-8101	.	_

46-1	8102-8104	We	_
46-2	8105-8114	regressed	_
46-3	8115-8116	1	_
46-4	8117-8118	)	_
46-5	8119-8122	six	_
46-6	8123-8133	parameters	_
46-7	8134-8142	obtained	_
46-8	8143-8145	by	_
46-9	8146-8156	correction	_
46-10	8157-8160	for	_
46-11	8161-8166	rigid	_
46-12	8167-8171	body	_
46-13	8172-8176	head	_
46-14	8177-8183	motion	_
46-15	8184-8185	,	_
46-16	8186-8187	2	_
46-17	8188-8189	)	_
46-18	8190-8193	the	_
46-19	8194-8200	signal	_
46-20	8201-8209	averaged	_
46-21	8210-8214	over	_
46-22	8215-8218	the	_
46-23	8219-8224	whole	_
46-24	8225-8230	brain	_
46-25	8231-8232	,	_
46-26	8233-8234	3	_
46-27	8235-8236	)	_
46-28	8237-8240	the	_
46-29	8241-8247	signal	_
46-30	8248-8256	averaged	_
46-31	8257-8261	over	_
46-32	8262-8265	the	_
46-33	8266-8276	ventricles	_
46-34	8277-8278	,	_
46-35	8279-8282	and	_
46-36	8283-8284	4	_
46-37	8285-8286	)	_
46-38	8287-8290	the	_
46-39	8291-8297	signal	_
46-40	8298-8306	averaged	_
46-41	8307-8311	over	_
46-42	8312-8315	the	_
46-43	8316-8320	deep	_
46-44	8321-8329	cerebral	_
46-45	8330-8335	white	_
46-46	8336-8342	matter	_
46-47	8343-8344	.	_

47-1	8345-8349	BOLD	_
47-2	8350-8354	data	_
47-3	8355-8359	were	_
47-4	8360-8369	projected	_
47-5	8370-8372	to	_
47-6	8373-8376	the	_
47-7	8377-8387	FreeSurfer	_
47-8	8388-8389	(	_
47-9	8390-8395	4.5.0	_
47-10	8396-8397	)	_
47-11	8398-8406	cortical	_
47-12	8407-8413	ribbon	_
47-13	8414-8416	of	_
47-14	8417-8421	each	_
47-15	8422-8433	participant	_
47-16	8434-8435	,	_
47-17	8436-8439	and	_
47-18	8440-8444	then	_
47-19	8445-8453	assessed	_
47-20	8454-8457	for	_
47-21	8458-8469	correlation	_
47-22	8470-8479	structure	_
47-23	8480-8487	between	_
47-24	8488-8491	122	_
47-25	8492-8505	surface-based	_
47-26	8506-8513	regions	_
47-27	8514-8516	of	_
47-28	8517-8525	interest	_
47-29	8526-8527	(	_
47-30	8528-8533	sROIs	_
47-31	8534-8535	,	_
47-32	8536-8538	61	_
47-33	8539-8542	per	_
47-34	8543-8553	hemisphere	_
47-35	8554-8555	)	_
47-36	8556-8563	derived	_
47-37	8564-8568	from	_
47-38	8569-8572	the	_
47-39	8573-8576	Yeo	_
47-40	8577-8579	et	_
47-41	8580-8582	al	_
47-42	8583-8584	.	_

48-1	8585-8595	17-network	_
48-2	8596-8608	parcellation	_
48-3	8609-8610	,	_
48-4	8611-8616	which	_
48-5	8617-8619	is	_
48-6	8620-8628	publicly	_
48-7	8629-8638	available	_
48-8	8639-8642	for	_
48-9	8643-8651	download	_
48-10	8652-8653	(	_
48-11	8654-8659	https	_
48-12	8660-8661	:	_
48-13	8662-8726	//surfer.nmr.mgh.harvard.edu/fswiki/CorticalParcellation_Yeo2011	_
48-14	8727-8728	)	_
48-15	8729-8730	.	_

49-1	8731-8743	Specifically	_
49-2	8744-8745	,	_
49-3	8746-8748	we	_
49-4	8749-8757	computed	_
49-5	8758-8765	Pearson	_
49-6	8766-8777	correlation	_
49-7	8778-8790	coefficients	_
49-8	8791-8798	between	_
49-9	8799-8803	each	_
49-10	8804-8812	regional	_
49-11	8813-8817	fMRI	_
49-12	8818-8822	time	_
49-13	8823-8829	course	_
49-14	8830-8831	,	_
49-15	8832-8840	averaged	_
49-16	8841-8847	across	_
49-17	8848-8851	all	_
49-18	8852-8860	vertices	_
49-19	8861-8867	within	_
49-20	8868-8871	the	_
49-21	8872-8878	region	_
49-22	8879-8880	,	_
49-23	8881-8884	and	_
49-24	8885-8888	the	_
49-25	8889-8893	mean	_
49-26	8894-8898	fMRI	_
49-27	8899-8903	time	_
49-28	8904-8910	course	_
49-29	8911-8914	for	_
49-30	8915-8920	every	_
49-31	8921-8926	other	_
49-32	8927-8933	region	_
49-33	8934-8935	.	_

50-1	8936-8939	The	_
50-2	8940-8948	regional	_
50-3	8949-8960	correlation	_
50-4	8961-8967	values	_
50-5	8968-8972	were	_
50-6	8973-8986	z-transformed	_
50-7	8987-8989	to	_
50-8	8990-9001	approximate	_
50-9	9002-9011	normality	_
50-10	9012-9015	and	_
50-11	9016-9020	then	_
50-12	9021-9029	compared	_
50-13	9030-9036	across	_
50-14	9037-9040	the	_
50-15	9041-9047	groups	_
50-16	9048-9053	using	_
50-17	9054-9059	ANOVA	_
50-18	9060-9065	after	_
50-19	9066-9072	linear	_
50-20	9073-9083	regression	_
50-21	9084-9086	of	_
50-22	9087-9090	age	_
50-23	9091-9092	,	_
50-24	9093-9096	sex	_
50-25	9097-9098	,	_
50-26	9099-9102	and	_
50-27	9103-9107	race	_
50-28	9108-9109	.	_

51-1	9110-9113	All	_
51-2	9114-9119	tests	_
51-3	9120-9124	were	_
51-4	9125-9134	corrected	_
51-5	9135-9138	for	_
51-6	9139-9147	multiple	_
51-7	9148-9159	comparisons	_
51-8	9160-9165	using	_
51-9	9166-9167	a	_
51-10	9168-9173	false	_
51-11	9174-9183	discovery	_
51-12	9184-9188	rate	_
51-13	9189-9190	(	_
51-14	9191-9194	FDR	_
51-15	9195-9196	)	_
51-16	9197-9199	of	_
51-17	9200-9201	q	_
51-18	9202-9203	<	_
51-19	9204-9208	0.05	_
51-20	9209-9210	,	_
51-21	9211-9224	corresponding	_
51-22	9225-9227	in	_
51-23	9228-9232	this	_
51-24	9233-9237	data	_
51-25	9238-9241	set	_
51-26	9242-9244	to	_
51-27	9245-9246	−	_
51-28	9247-9250	log	_
51-29	9251-9252	P	_
51-30	9253-9259	=1.411	_
51-31	9260-9263	FDR	_
51-32	9264-9273	corrected	_
51-33	9274-9275	.	_

